SMARCB1 and ataxia telangiectasia: Complete loss of SMARCB1 was initially identified in difficult-to-treat pediatric tumors such as malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (AT/RT) [26,27].